Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy.
about
Association of Interferon Gamma +874T/A Polymorphism and Leukemia Risk: A Meta-AnalysisTreatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studiesPrediction of Bacillus Calmette-Guerin Response in Patients with Bladder Cancer after Transurethral Resection of Bladder Tumor by Using Genetic Variation Based on Genomic StudiesSystematic review and meta-analysis on the association between IL-1B polymorphisms and cancer riskIL1 receptor antagonist gene IL1-RN variable number of tandem repeats polymorphism and cancer risk: a literature review and meta-analysis.IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking StatusGene Variants in Predicting BCG Response to Urinary Bladder Cancer.Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study.Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response.BCG response prediction with cytokine gene variants and bladder cancer: where we are?Targeting the tumor microenvironment by immunotherapy: part 2.Lack of association between interferon gamma +874 T/A polymorphism and cancer risk: an updated meta-analysis.The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria.IL-1RN VNTR polymorphism and genetic susceptibility to cervical cancer in Portugal.Cytotoxic T lymphocyte antigen 4 (CTLA4) gene polymorphism with bladder cancer risk in North Indian population.
P2860
Q26750761-5F45C40C-A7A5-4B71-B0D8-7C906F18673EQ26775541-8190EF3C-E355-4BA0-96DA-1B9CC96165CBQ28076563-56F9F6CE-159B-48FA-B88C-7F6F7A503EF4Q28383264-0196E826-C7F5-412E-8DD1-07FE3FAC4102Q31103501-3E99F207-66A2-4444-9079-DB586ED286D7Q33992811-1022B72F-3A5F-410F-AAE4-DD4CF645136BQ35777730-76780ED2-4AE1-4CE3-9947-CE8EF366C55BQ35944928-5EFB5B5A-4354-422D-B1CB-9377DA3260A6Q36167778-B5D764CD-DF06-4FA2-971D-4129D54F9921Q37773294-63E757F2-C8AF-43CA-B048-FC26939A4F53Q37797468-7490DDC2-4B1A-4E42-8887-CAA7BCC7AA27Q37935658-4F635ABE-9F29-48BA-B474-CE34DDEB52E6Q37952796-3A69CF50-9777-4344-8C0A-D5132D70721DQ46911442-F5486535-7649-4EBF-B4A6-E97FC6CBB63FQ51532088-0DC56EB9-440A-468C-8DD0-6933A0788D1BQ52802364-C4D8ABA3-80E6-4DB5-9383-F0EF5D3794A8Q54229184-5005FCDB-D215-439B-9C35-CF3B207B2610
P2860
Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Cytokine gene polymorphisms ar ...... rence after BCG immunotherapy.
@en
Cytokine gene polymorphisms ar ...... rence after BCG immunotherapy.
@nl
type
label
Cytokine gene polymorphisms ar ...... rence after BCG immunotherapy.
@en
Cytokine gene polymorphisms ar ...... rence after BCG immunotherapy.
@nl
prefLabel
Cytokine gene polymorphisms ar ...... rence after BCG immunotherapy.
@en
Cytokine gene polymorphisms ar ...... rence after BCG immunotherapy.
@nl
P2093
P2860
P1433
P1476
Cytokine gene polymorphisms ar ...... rence after BCG immunotherapy.
@en
P2093
Anil Mandhani
Anita Agrahari
Dinesh K Ahirwar
Rama D Mittal
P2860
P304
P356
10.1080/13547500902818246
P577
2009-06-01T00:00:00Z